EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Coagulation abnormalities associated with CAR ‐T‐cell therapy in haematological malignancies: A review

Xiaojuan Peng iD, Xialin Zhang, Meiling Zhao, Doudou Chang, Linhua Yang iD, Heng Mei iD, Ruijuan Zhang iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19583 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Xiaojuan Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hos…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Hematologic Neoplasms, Blood Coagulation Disorders. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Shanxi Bethune Talent Foundation Project, the Basic Research Project of Shanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)‐T‐cell therapy has demonstrated considerable efficacy and safety in the treatment of patients with relapsed/refractory haematological malignancies. Owing to significant advances, CAR‐T‐cell therapeutic modality has undergone substantial shifts in its clinical application. Coagulation abnormalities, which are prevalent complications in CAR‐T‐cell therapy, can range in severity from simple abnormalities in coagulation parameters to serious haemorrhage or disseminated intravascular coagulation associated with life‐threatening multiorgan dysfunction. Nonetheless, there is a lack of a comprehensive overview concerning the coagulation abnormalities associated with CAR‐T‐cell therapy. With an aim to attract heightened clinical focus and to enhance the safety of CAR‐T‐cell therapy, this review presents the characteristics of the coagulation abnormalities associated with CAR‐T‐cell therapy, including clinical manifestations, coagulation parameters, pathogenesis, risk factors and their influence on treatment efficacy in patients receiving CAR‐T‐cell infusion. Due to limited data, these conclusions may undergo changes as more experience accumulates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveHematologic NeoplasmsBlood Coagulation DisordersHumansReceptors, Chimeric Antigen

Stichwörter der Autor:innen

bleedingchimeric antigen receptor (CAR)‐T cellcoagulation disordersdisseminated intravascular coagulationhaematological malignanciesthrombosis

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, ShanXi, China.
  • Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, ShanXi, China.
  • Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

ORCID-Profile: Xiaojuan Peng, Linhua Yang, Heng Mei, Ruijuan Zhang

Förderung

  • Shanxi Bethune Talent Foundation Project
  • the Basic Research Project of Shanxi Province

Zitieren

APA

Peng, X., Zhang, X., Zhao, M., Chang, D., Yang, L., Mei, H., & Zhang, R. (2024). Coagulation abnormalities associated with CAR ‐T‐cell therapy in haematological malignancies: A review. British Journal of Haematology. https://doi.org/10.1111/bjh.19583

Vancouver

Peng X, Zhang X, Zhao M, Chang D, Yang L, Mei H, et al. Coagulation abnormalities associated with CAR ‐T‐cell therapy in haematological malignancies: A review. British Journal of Haematology. 2024. doi:10.1111/bjh.19583

BibTeX
@article{Peng2024,
  author = {Peng, Xiaojuan and Zhang, Xialin and Zhao, Meiling and Chang, Doudou and Yang, Linhua and Mei, Heng and Zhang, Ruijuan},
  title = {Coagulation abnormalities associated with CAR ‐T‐cell therapy in haematological malignancies: A review},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19583}
}
Kostenlos starten →